{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:25:40Z","timestamp":1793190340782,"version":"4.5.0"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>The cardiovascular benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may vary by body mass index (BMI), but evidence on BMI-specific outcomes remains limited.<\/jats:p><\/jats:sec>Objective<\/jats:title>To investigate the associations of GLP-1 RA use with cardiovascular and kidney outcomes across BMI categories in patients with type 2 diabetes.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This retrospective cohort study used the Chang Gung Research Database, a clinical dataset covering multiple hospitals in Taiwan. Patients with type 2 diabetes who received GLP-1 RAs or dipeptidyl peptidase-4 (DPP-4) inhibitors between 2011 and 2022 were identified. DPP-4 inhibitors were selected as the comparator due to their widespread use as a second-line oral hypoglycemic agent and their relatively neutral cardiovascular and kidney effects reported in previous studies. Propensity score matching was applied separately within BMI categories less than 25 and 25 or greater using a comprehensive set of demographic, clinical, and biochemical variables to balance baseline characteristics between treatment groups. The analysis was conducted from December 15, 2023, to July 5, 2024.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Initiation of GLP-1 RAs compared with DPP-4 inhibitors.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Primary outcomes included major adverse cardiovascular events (MACE; defined as cardiovascular death, myocardial infarction, ischemic stroke, or hospitalization for heart failure) and composite kidney outcomes (defined as estimated glomerular filtration rate decline \u226550% or progression to dialysis).<\/jats:p><\/jats:sec>Results<\/jats:title>Among 97\u202f156 patients with diabetes identified, a total of 7200 matched patients (mean [SD] age, 57.4 [14.2] years; 7473 [51.9%] female) were included (1841 pairs with BMI &amp;lt;25 and 5359 pairs with BMI \u226525). Among patients with BMI 25 or greater, GLP-1 RAs were associated with lower risks of cardiovascular death (hazard ratio [HR], 0.62; 95% CI, 0.46-0.83) and hospitalization for heart failure (subdistribution HR, 0.77; 95% CI, 0.62-0.94). Kidney outcomes were consistent across BMI strata. Restricted cubic spline analysis revealed increasing cardiovascular benefit associated with GLP-1 RAs among patients with higher BMI.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study of patients with type 2 diabetes, GLP-1 RAs use was associated with BMI-dependent cardiovascular benefits and consistent kidney protection, suggesting the importance of BMI stratification in guiding treatment decisions.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.30952","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:00:38Z","timestamp":1757343638000},"page":"e2530952","source":"Crossref","is-referenced-by-count":28,"title":["GLP-1 RAs and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes"],"prefix":"10.1001","volume":"8","author":[{"given":"Tien-Hsing","family":"Chen","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan, Taiwan"},{"name":"School of Traditional Chinese Medicine, Chang Gung University, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"En-Hao","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Yi","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien-Shin","family":"Chou","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Shyan","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning-I.","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Yung","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Jui","family":"Hung","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Lung","family":"Tsai","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, New Taipei Municipal TuCheng Hospital, New Taipei, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan, Taiwan"},{"name":"College of Management, Chang Gung University, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"issue":"1","key":"zoi250869r1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of type 2 diabetes\u2014global burden of disease and forecasted trends.","volume":"10","author":"Khan","year":"2020","journal-title":"J Epidemiol Glob Health"},{"issue":"7","key":"zoi250869r2","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1185\/03007995.2016.1168291","article-title":"Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus.","volume":"32","author":"Iglay","year":"2016","journal-title":"Curr Med Res Opin"},{"issue":"10193","key":"zoi250869r3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"zoi250869r4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"zoi250869r5","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi250869r6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial.","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"zoi250869r7","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial.","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"issue":"7","key":"zoi250869r8","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.cardfail.2023.03.017","article-title":"Increased risk of heart failure hospitalization with GLP-1 receptor agonists in patients with reduced ejection fraction: a meta-analysis of the EXSCEL and FIGHT trials.","volume":"29","author":"Neves","year":"2023","journal-title":"J Card Fail"},{"issue":"12","key":"zoi250869r9","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity.","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"issue":"24","key":"zoi250869r10","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes.","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"14","key":"zoi250869r11","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes.","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi250869r12","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes.","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi250869r13","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies.","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"zoi250869r14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.7570\/jomes23031","article-title":"Diagnosis of obesity: 2022 update of clinical practice guidelines for obesity by the Korean Society for the Study of Obesity.","volume":"32","author":"Haam","year":"2023","journal-title":"J Obes Metab Syndr"},{"issue":"3","key":"zoi250869r15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1507\/endocrj.EJ23-0593","article-title":"Definition, criteria, and core concepts of guidelines for the management of obesity disease in Japan.","volume":"71","author":"Ogawa","year":"2024","journal-title":"Endocr J"},{"issue":"5","key":"zoi250869r16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.bj.2017.08.002","article-title":"Chang Gung Research Database: a multi-institutional database consisting of original medical records.","volume":"40","author":"Tsai","year":"2017","journal-title":"Biomed J"},{"issue":"5","key":"zoi250869r17","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/pds.4713","article-title":"The Chang Gung Research Database\u2014a multi-institutional electronic medical records database for real-world epidemiological studies in Taiwan.","volume":"28","author":"Shao","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"zoi250869r18","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-024-02443-6","article-title":"Glucagon-like peptide 1 receptor agonists outperform basal insulin in cardiovascular and renal outcomes for type 2 diabetes mellitus: a retrospective cohort study.","author":"Chen","year":"2025","journal-title":"Acta Diabetol"},{"issue":"2","key":"zoi250869r19","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies.","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"issue":"446","key":"zoi250869r20","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk.","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"9","key":"zoi250869r21","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s00424-020-02417-x","article-title":"Glucose transporters in adipose tissue, liver, and skeletal muscle in metabolic health and disease.","volume":"472","author":"Chadt","year":"2020","journal-title":"Pflugers Arch"},{"issue":"1","key":"zoi250869r22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2337\/db23-0356","article-title":"Weight loss-independent effect of liraglutide on insulin sensitivity in individuals with obesity and prediabetes.","volume":"73","author":"Mashayekhi","year":"2024","journal-title":"Diabetes"},{"issue":"5","key":"zoi250869r23","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.2337\/db05-1360","article-title":"Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor.","volume":"55","author":"Cani","year":"2006","journal-title":"Diabetes"},{"issue":"11","key":"zoi250869r24","doi-asserted-by":"publisher","first-page":"4140","DOI":"10.1111\/bcp.14855","article-title":"Impact of glucagon-like peptide-1 receptor agonists on adiponectin concentrations: a meta-analysis of randomized controlled trials.","volume":"87","author":"Simental-Mend\u00eda","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"zoi250869r25","doi-asserted-by":"publisher","first-page":"851","DOI":"10.5114\/aoms.2016.58928","article-title":"Obesity and inflammation: the linking mechanism and the complications.","volume":"13","author":"Ellulu","year":"2017","journal-title":"Arch Med Sci"},{"issue":"4","key":"zoi250869r26","first-page":"504","article-title":"Obesity and obesity-induced inflammatory disease contribute to atherosclerosis: a review of the pathophysiology and treatment of obesity.","volume":"11","author":"Henning","year":"2021","journal-title":"Am J Cardiovasc Dis"},{"issue":"8","key":"zoi250869r27","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential.","volume":"17","author":"Ma","year":"2021","journal-title":"Int J Biol Sci"},{"issue":"9","key":"zoi250869r28","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1007\/s00125-012-2592-3","article-title":"Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes.","volume":"55","author":"Lee","year":"2012","journal-title":"Diabetologia"},{"issue":"11","key":"zoi250869r29","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1016\/j.numecd.2021.07.015","article-title":"Effects of GLP-1 receptor agonists on myokine levels and pro-inflammatory cytokines in patients with type 2 diabetes mellitus.","volume":"31","author":"Guarnotta","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"zoi250869r30","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists.","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol Res"},{"issue":"24","key":"zoi250869r31","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes.","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"issue":"1","key":"zoi250869r32","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.clinthera.2014.11.008","article-title":"Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis.","volume":"37","author":"Sun","year":"2015","journal-title":"Clin Ther"},{"issue":"2","key":"zoi250869r33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11906-015-0621-6","article-title":"GLP-1 agonists and blood pressure: a review of the evidence.","volume":"18","author":"Goud","year":"2016","journal-title":"Curr Hypertens Rep"},{"key":"zoi250869r34","doi-asserted-by":"publisher","first-page":"d7771","DOI":"10.1136\/bmj.d7771","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.","volume":"344","author":"Vilsb\u00f8ll","year":"2012","journal-title":"BMJ"},{"issue":"1","key":"zoi250869r35","first-page":"17","article-title":"Type II diabetes mellitus and cardiovascular risk factors: current therapeutic approaches.","volume":"12","author":"Kalofoutis","year":"2007","journal-title":"Exp Clin Cardiol"},{"issue":"11","key":"zoi250869r36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2019.03.006","article-title":"Lean mass abnormalities in heart failure: the role of sarcopenia, sarcopenic obesity, and cachexia.","volume":"45","author":"Carbone","year":"2020","journal-title":"Curr Probl Cardiol"},{"issue":"2-3","key":"zoi250869r37","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1159\/000094334","article-title":"Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans.","volume":"73","author":"Gutzwiller","year":"2006","journal-title":"Digestion"},{"issue":"5","key":"zoi250869r38","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/nm.3128","article-title":"GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure.","volume":"19","author":"Kim","year":"2013","journal-title":"Nat Med"},{"issue":"1-3","key":"zoi250869r39","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.regpep.2006.12.016","article-title":"Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells.","volume":"141","author":"Schlatter","year":"2007","journal-title":"Regul Pept"},{"issue":"2","key":"zoi250869r40","doi-asserted-by":"publisher","first-page":"F355","DOI":"10.1152\/ajprenal.00729.2010","article-title":"Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1.","volume":"301","author":"Crajoinas","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"zoi250869r41","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"issue":"3","key":"zoi250869r42","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11154-014-9287-7","article-title":"Effects of GLP-1 in the kidney.","volume":"15","author":"Skov","year":"2014","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"zoi250869r43","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.bbrc.2017.11.076","article-title":"Recombinant human GLP-1(rhGLP-1) alleviating renal tubulointestitial injury in diabetic STZ-induced rats.","volume":"495","author":"Yin","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"zoi250869r44","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1111\/dom.14160","article-title":"Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials.","volume":"22","author":"Verma","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"zoi250869r45","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.706908","article-title":"GLP-1 receptor: a new target for sepsis.","volume":"12","author":"Yang","year":"2021","journal-title":"Front Pharmacol"},{"issue":"2","key":"zoi250869r46","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00395-015-0465-x","article-title":"Gliptin and GLP-1 analog treatment improves survival and vascular inflammation\/dysfunction in animals with lipopolysaccharide-induced endotoxemia.","volume":"110","author":"Steven","year":"2015","journal-title":"Basic Res Cardiol"},{"issue":"5-6","key":"zoi250869r47","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00210-010-0559-9","article-title":"GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats.","volume":"382","author":"Ku","year":"2010","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"2","key":"zoi250869r48","doi-asserted-by":"publisher","first-page":"438","DOI":"10.2337\/db06-0738","article-title":"Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1.","volume":"56","author":"de Heer","year":"2007","journal-title":"Diabetes"},{"issue":"3-4","key":"zoi250869r49","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists.","volume":"11","author":"Filippatos","year":"2014","journal-title":"Rev Diabet Stud"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2838602\/chen_2025_oi_250869_1756497055.56421.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:00:39Z","timestamp":1757343639000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2838602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.30952","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]}}}